Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature

Jochen Schmitt, Gottfried WozelDepartment of Dermatology, Medical Faculty Carl Gustav Carus, Technische Universit&auml;t Dresden, GermanyAbstract: Psoriasis is a chronic inflammatory disease affecting 2% to 3% of the population in Western countries. Psoriasis is associated with limited quali...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jochen Schmitt, Gottfried Wozel
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c526050e9bc84e4482597d9c87165996
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c526050e9bc84e4482597d9c87165996
record_format	dspace
spelling	oai:doaj.org-article:c526050e9bc84e4482597d9c871659962021-12-02T05:37:41ZTargeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature1177-54751177-5491https://doaj.org/article/c526050e9bc84e4482597d9c871659962009-06-01T00:00:00Zhttp://www.dovepress.com/targeted-treatment-of-psoriasis-with-adalimumaba-critical-appraisal-ba-a3251https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Jochen Schmitt, Gottfried WozelDepartment of Dermatology, Medical Faculty Carl Gustav Carus, Technische Universit&auml;t Dresden, GermanyAbstract: Psoriasis is a chronic inflammatory disease affecting 2% to 3% of the population in Western countries. Psoriasis is associated with limited quality of life, cardiovascular disease, and depression. The approval of injectable biological agents has revolutionized the management of moderate to severe psoriasis. Adalimumab is a human monoclonal antibody against tumor necrosis factor (TNF) alpha approved for moderate-to-severe plaque-type psoriasis and psoriatic arthritis (PsA). This systematic review summarizes the evidence concerning the efficacy, clinical effectiveness, safety, and cost-effectiveness of adalimumab in the treatment of psoriasis. Five randomized controlled trials demonstrated the efficacy of adalimumab in moderate-to-severe plaque-type psoriasis and PsA with PASI-75 response rates of 53% to 80% and ACR-20 response rates of 39% to 58% after 12 to 16 weeks of treatment. In clinical practice patients who have not responded to one TNF antagonist may respond to another TNF antagonist. Adalimumab has similar or better cost-effectiveness than other biologics, but is less efficient than methotrexate and cyclosporine. Adalimumab is generally well tolerated. Patients should be evaluated for active/latent tuberculosis, serious infections, and other contraindications prior to initiation of adalimumab therapy. Future studies should investigate the comparative efficacy of adalimumab and other biologic and prebiologic agents. Recently established registries will yield additional data on the effectiveness and long-term safety of adalimumab.Keywords: adalimumab, biologic, efficacy, effectiveness, efficiency, psoriasis, treatment, safety Jochen SchmittGottfried WozelDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 303-318 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Jochen Schmitt Gottfried Wozel Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature
description	Jochen Schmitt, Gottfried WozelDepartment of Dermatology, Medical Faculty Carl Gustav Carus, Technische Universit&auml;t Dresden, GermanyAbstract: Psoriasis is a chronic inflammatory disease affecting 2% to 3% of the population in Western countries. Psoriasis is associated with limited quality of life, cardiovascular disease, and depression. The approval of injectable biological agents has revolutionized the management of moderate to severe psoriasis. Adalimumab is a human monoclonal antibody against tumor necrosis factor (TNF) alpha approved for moderate-to-severe plaque-type psoriasis and psoriatic arthritis (PsA). This systematic review summarizes the evidence concerning the efficacy, clinical effectiveness, safety, and cost-effectiveness of adalimumab in the treatment of psoriasis. Five randomized controlled trials demonstrated the efficacy of adalimumab in moderate-to-severe plaque-type psoriasis and PsA with PASI-75 response rates of 53% to 80% and ACR-20 response rates of 39% to 58% after 12 to 16 weeks of treatment. In clinical practice patients who have not responded to one TNF antagonist may respond to another TNF antagonist. Adalimumab has similar or better cost-effectiveness than other biologics, but is less efficient than methotrexate and cyclosporine. Adalimumab is generally well tolerated. Patients should be evaluated for active/latent tuberculosis, serious infections, and other contraindications prior to initiation of adalimumab therapy. Future studies should investigate the comparative efficacy of adalimumab and other biologic and prebiologic agents. Recently established registries will yield additional data on the effectiveness and long-term safety of adalimumab.Keywords: adalimumab, biologic, efficacy, effectiveness, efficiency, psoriasis, treatment, safety
format	article
author	Jochen Schmitt Gottfried Wozel
author_facet	Jochen Schmitt Gottfried Wozel
author_sort	Jochen Schmitt
title	Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature
title_short	Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature
title_full	Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature
title_fullStr	Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature
title_full_unstemmed	Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature
title_sort	targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/c526050e9bc84e4482597d9c87165996
work_keys_str_mv	AT jochenschmitt targetedtreatmentofpsoriasiswithadalimumabacriticalappraisalbasedonasystematicreviewoftheliterature AT gottfriedwozel targetedtreatmentofpsoriasiswithadalimumabacriticalappraisalbasedonasystematicreviewoftheliterature
_version_	1718400320825982976

Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature

Ejemplares similares